Diabetic Peripheral Neuropathy Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Helixmith, Lexicon Pharma, Glenmark Pharma, Regenacy Pharma

Posted on
by

Diabetic Peripheral Neuropathy Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Helixmith, Lexicon Pharma, Glenmark Pharma, Regenacy Pharma
The Diabetic Peripheral Neuropathy Market Forecast report offers an in-depth understanding of the Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the 7MM.

The Diabetic Peripheral Neuropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Peripheral Neuropathy pipeline products will significantly revolutionize the Diabetic Peripheral Neuropathy market dynamics.  

 

DelveInsight’s “Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Diabetic Peripheral Neuropathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Diabetic Peripheral Neuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Peripheral Neuropathy Market Insights

 

Some of the key facts of the Diabetic Peripheral Neuropathy Market Report: 

  • The Diabetic Peripheral Neuropathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • The estimated number of cases of painful peripheral neuropathy in the United States is expected to increase steadily at a compound annual growth rate (CAGR) of 4.6% during the study duration spanning from 2020 to 2034.

  • In December 2023, Vertex Pharmaceuticals revealed encouraging outcomes from its Phase II trial assessing the effectiveness of VX-548, a specific inhibitor targeting NaV1.8, in individuals suffering from painful diabetic peripheral neuropathy (DPN). Administering VX-548 resulted in a notable and meaningful decrease in the Numeric Pain Rating Scale (NPRS) from baseline, a primary measure, demonstrating both statistical significance and clinical relevance. Furthermore, the treatment exhibited good tolerability across all dosage levels examined during the study.

  • In 2023, the combined prevalent instances of diabetic peripheral neuropathy in the Seven Major Markets (7MM) amounted to approximately 34 million cases, with the United States exhibiting the highest prevalence of this condition.

  • By 2023, the greatest number of type-specific instances of diabetic neuropathy, particularly peripheral diabetic neuropathy, were noted in the Seven Major Markets (7MM). This trend is expected to potentially rise by 2034.

  • In 2023, the United States represented nearly half of all treated cases, a proportion anticipated to rise by 2034.

  • Bodman and Varacello (2023) reported that individuals diagnosed promptly with Type 1 diabetes mellitus can lower the likelihood of developing diabetic peripheral neuropathy by 78% through stringent glucose management. Conversely, for those diagnosed later with prolonged hyperglycemia or Type 2 diabetes, tight glucose control only offers a risk reduction ranging from 5% to 9%. 

  • Key Diabetic Peripheral Neuropathy Companies: Helixmith, Vertex Pharmaceuticals, Astrazeneca, Eli Lilly and Company, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eva Pharma, GlaxoSmithKline, and others

  • Key Diabetic Peripheral Neuropathy Therapies: ENGENSIS (VM202), VX-548, MEDI7352, LY3556050, pregabalin sustained-release tablets, RTA 901, LX9211 (blinded), JMKX000623, Alpha-Lipoic Acid (ALA), GSK3858279, and others

  • The Diabetic Peripheral Neuropathy epidemiology based on gender analyzed that the prevalence of Diabetic Peripheral Neuropathy increases significantly with age

 

Diabetic Peripheral Neuropathy Overview

Diabetic Peripheral Neuropathy (DPN) is a type of nerve damage that occurs as a complication of diabetes mellitus. It affects the peripheral nerves, which are the nerves outside the brain and spinal cord that connect the rest of the body to the central nervous system.

 

Get a Free sample for the Diabetic Peripheral Neuropathy Market Report:

https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market

 

Diabetic Peripheral Neuropathy Market  

The dynamics of the Diabetic Peripheral Neuropathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.  

 

Diabetic Peripheral Neuropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Diabetic Peripheral Neuropathy Epidemiology Segmentation:

The Diabetic Peripheral Neuropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Diabetic Peripheral Neuropathy

  • Prevalent Cases of Diabetic Peripheral Neuropathy by severity

  • Gender-specific Prevalence of Diabetic Peripheral Neuropathy

  • Diagnosed Cases of Episodic and Chronic Diabetic Peripheral Neuropathy

 

Download the report to understand which factors are driving Diabetic Peripheral Neuropathy epidemiology trends @ Diabetic Peripheral Neuropathy Epidemiological Insights

 

Diabetic Peripheral Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Peripheral Neuropathy market or expected to get launched during the study period. The analysis covers Diabetic Peripheral Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Peripheral Neuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Diabetic Peripheral Neuropathy treatment, visit @ Diabetic Peripheral Neuropathy Medications

 

Diabetic Peripheral Neuropathy Therapies and Key Companies

  • ENGENSIS (VM202): Helixmith

  • VX-548: Vertex Pharmaceuticals

  • MEDI7352: Astrazeneca

  • LY3556050: Eli Lilly and Company

  • pregabalin sustained-release tablets: CSPC Ouyi Pharmaceutical

  • RTA 901: Reata

  • LX9211 (blinded): Lexicon Pharmaceuticals

  • JMKX000623: Jemincare

  • Alpha-Lipoic Acid (ALA): Eva Pharma

  • GSK3858279: GlaxoSmithKline

 

Diabetic Peripheral Neuropathy Market Drivers

  • Low-cost off-label medications like gabapentin and tricyclic antidepressants are very effective, presenting patients with numerous treatment options for pain management. 

  • New treatment options like topical 8% capsaicin patch, new electrical stimulation methods are providing patients with safer and effective treatment options. 

 

Diabetic Peripheral Neuropathy Market Unmet Needs

  • Since the current treatment landscape lacks a disease-modifying treatment option and is solely dependent on symptomatic relief, emerging disease-modifying therapies can not only expect to have a high uptake, but they can also charge a significant premium price. 

  • Being very safe and non-addictive, CBD holds promise of becoming an optimal long term treatment option for pain management in the near future.

 

Scope of the Diabetic Peripheral Neuropathy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Diabetic Peripheral Neuropathy Companies: Helixmith, Vertex Pharmaceuticals, Astrazeneca, Eli Lilly and Company, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eva Pharma, GlaxoSmithKline, and others

  • Key Diabetic Peripheral Neuropathy Therapies: ENGENSIS (VM202), VX-548, MEDI7352, LY3556050, pregabalin sustained-release tablets, RTA 901, LX9211 (blinded), JMKX000623, Alpha-Lipoic Acid (ALA), GSK3858279, and others

  • Diabetic Peripheral Neuropathy Therapeutic Assessment: Diabetic Peripheral Neuropathy current marketed and Diabetic Peripheral Neuropathy emerging therapies

  • Diabetic Peripheral Neuropathy Market Dynamics: Diabetic Peripheral Neuropathy market drivers and Diabetic Peripheral Neuropathy market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Diabetic Peripheral Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Diabetic Peripheral Neuropathy Market Access and Reimbursement

 

Discover more about therapies set to grab major Diabetic Peripheral Neuropathy market share @ Diabetic Peripheral Neuropathy market forecast

 

Table of Contents 

1. Diabetic Peripheral Neuropathy Market Report Introduction

2. Executive Summary for Diabetic Peripheral Neuropathy

3. SWOT analysis of Diabetic Peripheral Neuropathy

4. Diabetic Peripheral Neuropathy Patient Share (%) Overview at a Glance

5. Diabetic Peripheral Neuropathy Market Overview at a Glance

6. Diabetic Peripheral Neuropathy Disease Background and Overview

7. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Peripheral Neuropathy 

9. Diabetic Peripheral Neuropathy Current Treatment and Medical Practices

10. Diabetic Peripheral Neuropathy Unmet Needs

11. Diabetic Peripheral Neuropathy Emerging Therapies

12. Diabetic Peripheral Neuropathy Market Outlook

13. Country-Wise Diabetic Peripheral Neuropathy Market Analysis (2020–2034)

14. Diabetic Peripheral Neuropathy Market Access and Reimbursement of Therapies

15. Diabetic Peripheral Neuropathy Market Drivers

16. Diabetic Peripheral Neuropathy Market Barriers

17.  Diabetic Peripheral Neuropathy Appendix

18. Diabetic Peripheral Neuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/